Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Zanubrutinib Oral Product
Zanubrutinib Product · 1 trial · 1 indication
To assess the improvement of the functional neurological outcome of participants after treatment with Zanubrutinib in combination with Rituximab by The Inflammatory Neuropathy Cause and Treatment (INCAT) disability score (Overall score is the sum of arm and leg disability, scaled 0 (no problems) to 5 (disabled). A proportion of patients with ≥2 points improvement on the INCAT disability score wil be used as primary endpoint
To assess the safety and tolerability of the combined treatment with Rituximab and Zanubrutinib
Dose adjustments made per patient.Registration of drug accountability (counting of remaining capsules after each treatment cycle). Drug accountability will be presented as percentage.
| Name | Type | Description |
|---|---|---|
| Zanubrutinib Oral Product | DRUG | Treatment will consist of Rituximab administered at 375 mg/m2 intravenously on Cycle 1 Days 1, 8, 15, 22 only (4 total infusions). The experimental part of the treatment will consist of Zanubrutinib, given once daily 320 mg (4 x 80 mg capsules). Although Zanubrutinib is taken continuously, therapy cycles are calculated per 28 days. Participants will be treated for a minimum of 6 cycles per protocol. Participants who still use Zanubrutinib at the end of study can continue indefinitely until registration and reimbursement in the Netherlands. |
Inclusion Criteria: * Able to provide written informed consent and understand and comply with the requirements of the study * Demyelinating PNP defined by the European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinemic demyelinating neuropathies...
Zanubrutinib Product is being studied for the treatment of Monoclonal Gammopathy of Uncertain Significance, specifically in patients with IgM monoclonal gammopathy and anti-MAG related polyneuropathy. It is an investigational small molecule kinase inhibitor currently in Phase 2 clinical development.
Zanubrutinib Product is a kinase inhibitor, as indicated by its -tinib suffix. It is being evaluated in a biomarker-selected patient population for the treatment of Monoclonal Gammopathy of Uncertain Significance.
Zanubrutinib Product is being developed by BeOne Medicines Ltd., a company listed under the ticker symbol ONC. The drug is currently in Phase 2 clinical development for Monoclonal Gammopathy of Uncertain Significance.
Zanubrutinib Product is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing trial is active but not recruiting participants.
Zanubrutinib Product is being studied in a single Phase 2 clinical trial with the identifier NCT05939037. The trial is titled 'Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Anti-MAG Related Polyneuropathy' and is enrolling 35 participants in the Netherlands.
Yes, Zanubrutinib Product is also known as Zanubrutinib Oral Product. Both names refer to the same investigational drug being developed by BeOne Medicines Ltd. for the treatment of Monoclonal Gammopathy of Uncertain Significance.